These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36030748)

  • 1. Global drug diffusion and innovation with the medicines patent pool.
    Wang LX
    J Health Econ; 2022 Sep; 85():102671. PubMed ID: 36030748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compulsory licensing and access to drugs.
    Stavropoulou C; Valletti T
    Eur J Health Econ; 2015 Jan; 16(1):83-94. PubMed ID: 24408475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Economic Theory of Patent Protection and Pandemic Influenza Vaccines: Do Patents Really Incentivize Innovation in the Field?
    Eccleston-Turner M
    Am J Law Med; 2016 May; 42(2-3):572-597. PubMed ID: 29086638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How drug life-cycle management patent strategies may impact formulary management.
    Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
    Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The procurement of innovation by the U.S. government.
    de Rassenfosse G; Jaffe A; Raiteri E
    PLoS One; 2019; 14(8):e0218927. PubMed ID: 31404070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patent lifecycle management strategies in open innovation projects.
    Lee Y; Fong EA
    Drug Discov Today; 2020 Oct; 25(10):1782-1785. PubMed ID: 32592662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
    Beall RF; Attaran A
    Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between the academic community and the pharmaceutical industry: the legislative background and its effect on spending on medical research and development.
    Matthews JH
    Clin Invest Med; 1996 Dec; 19(6):470-8. PubMed ID: 8959357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
    Cockburn I; Long G
    Expert Opin Ther Pat; 2015 Jul; 25(7):739-42. PubMed ID: 25927945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
    Arnold DG; Troyer JL
    J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can patent duration hinder medical innovation.
    Leoni P; Sandroni A
    Int J Health Econ Manag; 2016 Dec; 16(4):397-406. PubMed ID: 27878691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are patents impeding medical care and innovation?
    Gold ER; Kaplan W; Orbinski J; Harland-Logan S; N-Marandi S
    PLoS Med; 2010 Jan; 7(1):e1000208. PubMed ID: 20052274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure.
    Magazzini L; Pammolli F; Riccaboni M
    Eur J Health Econ; 2004 Jun; 5(2):175-82. PubMed ID: 15452754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.